<DOC>
	<DOCNO>NCT01508910</DOCNO>
	<brief_summary>The purpose study assess safety efficacy target intramyocardial delivery Auto-CD34+ cell increase exercise time amelioration anginal symptom subject refractory angina chronic myocardial ischemia .</brief_summary>
	<brief_title>Efficacy Safety Targeted Intramyocardial Delivery Auto CD34+ Stem Cells Improving Exercise Capacity Subjects With Refractory Angina</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<criteria>Main Male female participant 21 80 year age time sign informed consent . Participants Canadian Cardiovascular Society ( CCS ) class III IV chronic refractory angina . Participants without control angina symptom spite maximal tolerated dos antiangina drug . Participants must optimal therapy angina must stable antianginal medication regimen least 4 week sign informed consent form . Participants obstructive coronary disease unsuitable conventional revascularization due unsuitable anatomy comorbidity determine site confirm independent adjudication committee . Participants must evidence inducible myocardial ischemia . Participants must experience angina episode . Participants must able complete 2 exercise tolerance test treadmill within 3 week randomization . If female childbearing potential , subject must pregnant agree employ adequate birth control measure duration study . Main Cardiovascular hospitalization within 60 day prior potential study enrollment . Participant successful partially successful coronary artery bypass graft ( CABG ) within 6 month PCTA within 60 day potential study enrollment . Participant placement biventricular pacemaker cardiac resynchronization therapy ( CRT ) heart failure within 180 day potential study enrollment . Participant document stroke transient ischemic attack ( TIAs ) within 60 day potential study enrollment . Participant history moderate severe aortic stenosis ; severe aortic insufficiency ; severe mitral stenosis ; severe mitral insufficiency . Participant prosthetic aortic valve mechanical mitral valve replacement . Participant severe comorbidity associate reduction life expectancy le 3 year result chronic medical illness . Participants cancer exclude follow exception : Subjects insitu nonmelanoma skin cancer insitu cervical cancer exclude . Participants cancer free &gt; = 5 year determine oncologist exclude . Subjects prior history stem cell transplant cancer exclude matter long cancerfree . Participants history leukemia bone marrow disease . Participant sickle cell disease sickle cell trait . Participants proliferative retinopathy . Participants Hb A1c &gt; 9 % . Participant platelet count &gt; 10 % upper limit normal ( ULN ) platelet count &lt; 70,000 . Participant hematocrit &lt; 30 % prior potential study enrollment . Participant serum creatinine &gt; 2.5 mg/dL prior potential study enrollment . Participant test positive HIV , hepatitis B , hepatitis C , chronic immunosuppressive medication , previous stem cell transplant . Participant known contraindication Neupogen ( filgrastim ) GCSF . Participant previously enrol active treatment group cell therapy trial cardiovascular disease include phase CD34+ stem cell trial . Left ventricular ( LV ) thickness &lt; 7 mm target area injection measure 2D echocardiogram ( ECHO ) . Atrial fibrillation , atrial flutter , uncontrolled arrhythmia would prohibit accurate electromechanical mapping NOGAguided intramyocardial injection . Bleeding diathesis INR &gt; 1.8 receive antithrombotic therapy . Hepatic dysfunction evidence elevate AST ALT level &gt; 2.5 x ULN . Any previous transplant require immunosuppression . Disease state require chronic immunosuppression .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>